Asset Details
Do you wish to reserve the book?
Effects of paramylon‐rich Euglena gracilis EOD‐1 powder on visceral fat obesity in moderately obese Japanese adults: A randomized, double‐blind, placebo‐controlled, parallel‐group trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Effects of paramylon‐rich Euglena gracilis EOD‐1 powder on visceral fat obesity in moderately obese Japanese adults: A randomized, double‐blind, placebo‐controlled, parallel‐group trial
Do you wish to request the book?
Effects of paramylon‐rich Euglena gracilis EOD‐1 powder on visceral fat obesity in moderately obese Japanese adults: A randomized, double‐blind, placebo‐controlled, parallel‐group trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Effects of paramylon‐rich Euglena gracilis EOD‐1 powder on visceral fat obesity in moderately obese Japanese adults: A randomized, double‐blind, placebo‐controlled, parallel‐group trial
2023
Overview
To investigate whether supplementation of paramylon (PM)‐rich Euglena gracilis EOD‐1 powder (EOD‐1) reduces visceral fat obesity in moderately obese Japanese subjects. A randomized, double‐blind, placebo‐controlled intervention study was conducted involving 36 Japanese adults with a body mass index (BMI) ≥25 and <30 kg/m2. Subjects were randomly assigned into two groups to consume EOD‐1 capsules (EOD‐1 group, 2.6 g PM/day) or cellulose capsules (placebo group) for a 12‐week period. Anthropometric measurements including visceral fat area (VFA) and blood samples were measured at baseline and throughout the trial. There was no significant difference in VFA between the two groups, although subgroup analysis by gender showed a significant decrease in VFA in the male EOD‐1 group compared with the placebo group. Serum adiponectin levels in all subjects from the EOD‐1 group were significantly higher than in the placebo group. By comparison with the placebo group, the subjects in the EOD‐1 group showed a significant reduction in serum HbA1c levels. EOD‐1 intake led to a significant reduction in VFA in male subjects with moderate obesity (BMI 25–30 kg/m2). PM in EOD‐1 may contribute to preventing visceral fat obesity in male Japanese subjects. Moreover, PM may also contribute to improving glucose homeostasis in moderately obese Japanese adults. We studied whether paramylon‐rich Euglena gracilis EOD‐1 powder supplementation could improve visceral fat obesity. EOD‐1 was found to enhance VFA loss and increase serum adiponectin concentration in moderately obese male adult subjects after a 12‐week supplementation period (2.6 g/day PM). EOD‐1 may reduce the serum HbA1c concentration and HOMA‐R in both male and female subjects. Effect of PM EOD‐1 on visceral and subcutaneous fat areas (bars represent mean and SE). *: p < .05 (vs. baseline, paired t‐test), #: p < .05 (ANCOVA). □ baseline, ■ 12 weeks.
